MetLife director granted 189 deferred shares
MetLife director Diana McKenzie reported a small compensation-related share increase.
Rhea-AI Filing Summary
MetLife director Diana McKenzie reported a small compensation-related share increase. She acquired 189 shares of MetLife common stock on an imputed basis at $70.60 per share through reinvested dividends in the MetLife Deferred Compensation Plan for Non-Management Directors. Following this grant, she directly holds 23,751 common shares, reflecting routine deferred compensation rather than an open-market purchase.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 189 shares
Grant/Award
1 txn
Insider
MCKENZIE DIANA
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 189 | $70.60 | $13K |
Holdings After Transaction:
Common Stock — 23,751 shares (Direct)
Footnotes (1)
- F1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.
FAQ
What insider transaction did MetLife (MET) director Diana McKenzie report?
Diana McKenzie reported acquiring 189 shares of MetLife common stock. The shares were credited through imputed reinvestment of dividends under MetLife’s Deferred Compensation Plan for Non-Management Directors, rather than via an open-market stock purchase.
Was Diana McKenzie’s MetLife (MET) transaction an open-market stock purchase?
No, the transaction was not an open-market purchase. It was a grant-type acquisition where 189 shares were credited through imputed dividend reinvestment on deferred shares within MetLife’s non-management director deferred compensation plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.